EUVIMEDEUVIMED entdecken
Crossref

Enoxaparin thromboprophylaxis in hospitalized obese pediatric patients

Juwon Yim iD, Afrin Jahan, Nikolay Braykov, Nina D Murphy, Gary M Woods iD

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.30942 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Juwon Yim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Children's Healthcare of Atlanta, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Enoxaparin, Anticoagulants. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Enoxaparin is an anticoagulant used for pharmacologic thromboprophylaxis in pediatrics. Enoxaparin pharmacokinetics can be altered in the setting of obesity. Optimal enoxaparin dosing for thromboprophylaxis in children with obesity remains unclear. Procedure A retrospective review was conducted of pediatric patients who weighed ≥60 kg with BMI ≥ 95th percentile, received enoxaparin for thromboprophylaxis, and had at least one appropriately drawn anti‐factor Xa (anti‐Xa) from 2013 to 2022. Anti‐Xa levels were reviewed for patients initially treated with enoxaparin 30 mg every 12 h. The average daily enoxaparin dose required to achieve an anti‐Xa of 0.2–0.4 unit/mL, which was stratified by BMI percentile and weight, was calculated.

Results

Of 116 patients (median age 15.8 years) included for analysis, 106 patients were initially treated with enoxaparin 30 mg every 12 h. Anti‐Xa levels were 99th percentile and 54% of patients >100 kg. Ninety‐one patients had at least one anti‐Xa 0.2–0.4 unit/mL with an average daily enoxaparin dosing of 66 mg. When stratified by severity of obesity, higher doses were required to attain an anti‐Xa 0.2–0.4 unit/mL in patients with BMI > 99th percentile compared with those with 95th–99th percentile (67.8 ± 15.7 vs. 62 ± 5.6 mg/day, p = .01). Patients > 100 kg required significantly higher dose than those ≤100 kg (69.1 ± 15.5 vs 61.2 ± 7.3 mg/day, p = .002).

Conclusions

Increased initial dosing and/or anti‐Xa level monitoring should be considered in adolescents with severe obesity receiving enoxaparin thromboprophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EnoxaparinAnticoagulantsHumansAdolescentRetrospective StudiesFemaleMaleChildChild, PreschoolVenous ThromboembolismObesityPediatric ObesityFollow-Up StudiesFactor Xa Inhibitors

Stichwörter der Autor:innen

enoxaparinobesitypediatricsprophylaxis

Substanzen

EnoxaparinAnticoagulantsFactor Xa Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
  • Advanced Analytics and Outcomes Team/ Information Services and Technology, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
  • Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Department of Pediatrics, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

ORCID-Profile: Juwon Yim, Gary M Woods

Zitieren

APA

Yim, J., Jahan, A., Braykov, N., Murphy, N. D., & Woods, G. M. (2024). Enoxaparin thromboprophylaxis in hospitalized obese pediatric patients. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30942

Vancouver

Yim J, Jahan A, Braykov N, Murphy ND, Woods GM. Enoxaparin thromboprophylaxis in hospitalized obese pediatric patients. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30942

BibTeX
@article{Yim2024,
  author = {Yim, Juwon and Jahan, Afrin and Braykov, Nikolay and Murphy, Nina D and Woods, Gary M},
  title = {Enoxaparin thromboprophylaxis in hospitalized obese pediatric patients},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.30942}
}
Kostenlos starten →